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Abstract
Introduction
Obliterative vasculopathy and fibrosis are hallmarks of systemic sclerosis (SSc), a severe
systemic autoimmune disease. Bone marrow-derived mesenchymal stromal cells (MSCs)
from SSc patients may harbor disease-specific abnormalities. We hypothesized disturbed
vascular smooth muscle cell (VSMC) differentiation with increased propensity towards myo-
fibroblast differentiation in response to SSc-microenvironment defining growth factors and
determined responsible mechanisms.
Methods
We studied responses of multipotent MSCs from SSc-patients (SSc-MSCs) and healthy
controls (H-MSCs) to long-term exposure to CTGF, b-FGF, PDGF-BB or TGF-β1. Differenti-
ation towards VSMC and myofibroblast lineages was analyzed on phenotypic, biochemical,
and functional levels. Intracellular signaling studies included analysis of TGF-β receptor
regulation, SMAD, AKT, ERK1/2 and autocrine loops.
Results
VSMC differentiation towards both, contractile and synthetic VSMC phenotypes in response to
CTGF and b-FGF was disturbed in SSc-MSCs. H-MSCs and SSc-MSCs responded equally to
PDGF-BB with prototypic fibroblastic differentiation. TGF-β1 initiated myofibroblast differentia-
tion in both cell types, yet with striking phenotypic and functional differences: In relation to H-
MSC-derived myofibroblasts induced by TGF-β1, those obtained from SSc-MSCs expressed
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more contractile proteins, migrated towards TGF-β1, had low proliferative capacity, and
secreted higher amounts of collagen paralleled by reduced MMP expression. Higher levels of
TGF-β receptor 1 and enhanced canonical and noncanonical TGF-β signaling in SSc-MSCs
accompanied aberrant differentiation response of SSc-MSCs in comparison to H-MSCs.
Conclusions
Deregulated VSMC differentiation with a shift towards myofibroblast differentiation expands
the concept of disturbed endogenous regenerative capacity of MSCs from SSc patients.
Disease related intrinsic hyperresponsiveness to TGF-β1 with increased collagen produc-
tion may represent one responsible mechanism. Better understanding of repair barriers and
harnessing beneficial differentiation processes in MSCs could widen options of autologous
MSC application in SSc patients.
Introduction
Systemic sclerosis (SSc) is a complex progressive multisystem disorder featuring vasculopathy,
autoimmunity and extensive fibrosis of skin and organs [1]. SSc vasculopathy includes both,
microvascular and macrovascular changes. While capillary rarefaction is a morphologic
denominator of microvascular changes [2], occlusive macrovasculopathy of arterioles and
arteries features excessive neointima formation in parallel to medial and adventitial fibrosis [3].
Current concepts suggest that failure of vascular regeneration with an inappropriate local tissue
healing response may result in uncontrolled deposition of extracellular matrix which is central
to the pathogenesis of SSc [4].
Malfunctioning precursor and mature cells types contribute to this combination of defective
maintenance of vascular integrity and adverse pro-fibrotic tissue remodeling in response to
cytokine and growth factor (GF) microenvironmental stimuli. Recent data implicate defects in
endothelial cell progenitor (EPC) numbers and functions [5] together with SSc-related hypore-
sponsiveness to pro-angiogenic stimuli. Constitutively activated myofibroblasts derived from
lesional skin or fibrotic lungs from affected patients with excessive collagen production are
another paradigmatic example [1, 6]. Mesenchymal stromal cells (MSC) from SSc patients have
preserved expansion capacities, mesenchymal differentiation abilities, and immunomodulatory
properties [7], yet show defective differentiation towards endothelial lineage [8]. Although
MSCs are a potential myofibroblast source in fibroproliferative diseases [1], SSc specific changes
at the interface between myofibroblast and phenotypically overlapping vascular smooth muscle
cell (VSMC) differentiation have not been studied. VSMCs and myofibroblasts share many phe-
notypic features [9]. Similarly to VSMCs, MSCs bear a high potential for neointimal growth due
to their phenotypic plasticity [10, 11].
We hypothesized that multipotent bone marrow derived MSCs from SSc patients (SSc-
MSCs) harbor intrinsic differentiation abnormalities comprising the VSMC-myofibroblast axis
in response to disease associated microenviroment favoring a phenotypic switch towards myo-
fibroblasts. We compared features of phenotypic VSMC-myofibroblast conversion of MSCs
from healthy controls (H-MSCs) and SSc-MSCs in response to key mediators including con-
nective tissue growth factor (CTGF), basic fibroblast growth factor (b-FGF), platelet derived
growth factor-BB (PDGF-BB) and transforming growth factor-β1 (TGF-β1). To better under-
stand mechanisms responsible for phenoconversion of MSCs into SSc lesional cell types we
addressed differences in receptor expression, signaling pathways, and autocrine regulation.
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Methods
Patients and controls
We assayed MSCs from six representative patients with SSc and from six age- and sex-matched
healthy controls. Patients were between 38 and 74 years (median 50) of age; four were women
(67%). All patients had digital ulcers and suffered from pulmonary and skin fibrosis. Three had
limited cutaneous SSc, three had diffuse cutaneous SSc (dSSc) with a disease duration of 11–
120 month (median 92). All individuals with dSSc were positive for Scl-70 antibodies, the oth-
ers were either positive for anti-centromer or U1-RNP antibodies or had no detectable auto-
antibodies. Four patients received intermittent corticosteroid therapy. Controls were healthy
subjects without any sign of autoimmune or fibrotic diseases who donated bone marrow for
allogeneic transplantation. The study protocol was approved by the local institutional review
board (Ethikkomission der Charité –Universitätsmedizin Berlin). All subjects were included in
the study after providing written informed consent.
Isolation and culture of MSC
Up to 10 ml aspirated iliac crest bone marrow were diluted 1:2 with PBS (PAA) and layered
onto Percoll (density 1.124 g/ml; Biochrom, Berlin, Germany) diluted to a density of 1.068 g/
ml. After centrifugation at 800g for 20 min at room temperature, mononuclear cells (MNC)
were collected from the interphase, washed twice with PBS, and plated at a density of 4x104/
cm2 in α-MEM (#E15-862, PAA) supplemented with 100 U/mL penicillin (PAA), 100 μg/mL
streptomycin (PAA), 2 IU/ml heparin (Ratiopharm), and 5% freshly thawed platelet lysate
[12]. Cells were incubated at 37°C and 5% CO2. Non-adherent cells were washed off with PBS
after 2–3 days. Medium was changed twice a week.
When cultures reached about 90% confluence, cells were detached with 0.05% Trypsin/
0.02% EDTA (PAA), counted, and re-plated at 500 cells/cm2 in 175 cm2 flasks (Saarstedt).
Under these culture conditions, MSC maintain multilineage differentiation capacity, express
characteristic surface marker proteins (CD59, CD90, CD105), lack expression of hematopoetic
markers, and remain cytogenetically stable at least until passage 6 [12].
Cell stimulation
Passages 2 to 5 were used for experiments. For collagen and TGF-β1 secretion, mRNA and pro-
tein expression analyses as well as for signal transduction studies, 2x105 cells were plated per
60-mm dish in complete α-MEM. The next day, medium was changed to experimental
medium consisting of supplemented phenol red free DMEM (PAA) without PL or FCS. After
24 h, cells were changed to experimental medium containing either connective tissue growth
factor (CTGF; Immunotools), basic fibroblast growth factor (b-FGF; Immunotools), platelet
derived growth factor-BB (PDGF-BB; Sigma), or transforming growth factor-β1 (TGF- β1;
R&D). Each growth factor was used at 10 ng/mL. Medium was changed after 3 days. After
another 3 days, cell culture supernatants were collected, centrifuged at 10,000 g for 10 min and
stored at -20°C after discarding the pellets.
Phase contrast micrographs
Cultures were photographed after six days of growth factor (GF) stimulation using an inverted
phasecontrast microscope (Zeiss) and a CCD camera (Canon). The original magnification was
200x. Representative images of six independent experiments are shown.
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Immunofluorescence
Cells grown on glass coverslips were fixed with ice cold methanol. Unspecific binding was
blocked for 90 minutes at room temperature with 1% BSA in TBS. Anti-sm-α-actin antibody
(clone 1A4, Sigma) was added 1:400 in blocking solution for 2 h at room temperature. After
washing, an Alexa Fluor 488 labeled secondary antibody (1:500 in TBS) was used for detection
(1 h at room temperature in the dark). Nuclei were stained with 4',6-diamidino-2-phenylindole
(DAPI). Images were captured on a Zeiss Axioplan microscope.
Protein extraction and western blotting
Cells in culture dishes were washed twice with PBS. 80 μl of ice cold lysis buffer (50 mM Tris,
pH 7.5; 0.01% SDS; 0.5% Triton X-100; complete mini protease inhibitor cocktail (Roche); 10
mMNaF; 1 mM Na3VO4; 10 mM β-glycerophosphate; 2 mM sodium pyrophosphate) were
added and cells were scraped into micro tubes. Lysates were passed five times through a
26-gauge needle, cleared by centrifugation at 10,000 g for 10 min at 4°C, and stored at –20°C
until analysis. Total protein content was determined with the DC protein assay (Bio-rad,
Munich, Germany).
Equal amounts of protein were separated by SDS-polyacrylamide gel electrophoresis under
reducing conditions and transferred onto nitrocellulose membranes (Hybond-ECL, Amersham
Biosciences, Freiburg, Germany) by electroblotting. Membranes were blocked with 5% non-fat
dry milk in TBS containing 0.1% Tween 20 (TBST) for 1 h at room temperature. The following
primary antibodies were diluted in blocking solution or 3% BSA/TBST and allowed to bind
over night at 4°C: COL2A1 (clone M2139; Santa Cruz) 1:500, SM22α (polyclonal; Abcam)
1:10,000, sm-Calponin (clone hCP; Sigma) 1:1,000, myosin light chain kinase (clone K36;
Sigma) 1:500, sm-α-actin (clone 1A4; Sigma) 1:20,000, pSMAD3-Ser423/425 (clone C25A9)
1:500, pAKT-Ser473 (clone D9E) 1:1,000, total AKT (polyclonal) 1:1,000, pERK1/2-Thr202/
Tyr204 1:3,000 (clone D13.14.4E), total EKR1/2 1:1,000 (polyclonal; all from Cell Signaling
Technology), TGFβ receptor I (clone V-22; Santa Cruz) 1:1,000, α-tubulin (DM1A; Sigma)
1:10,000, GAPDH (clone FL-335; Santa Cruz) 1:500. After incubation with the appropriate
horseradish peroxydase-conjugated secondary antibodies (1:25,000 in TBST; Dianova), immu-
noreactive proteins were detected by chemiluminescence (Super Signal West regular, pico, or
dura, Thermo Scientific). Band intensities were quantified using ImageJ 1.41i software.
Ca2+ imaging
In six-well-plates, 75,000 cells per well were seeded onto glass coverslips in complete α-MEM
and allowed to adhere overnight. Medium was switched to phenol red free DMEM without
FCS or PL for 24 h. After treatment with GF in experimental medium for 6 days, cells were
loaded with the Ca2+ indicator fluo-4-AM (Invitrogen, Karlsruhe, Germany) (10 μM) and
pluronic acid (Merck, Darmstadt, Germany) (0.01%; w/v) for 30 min at room temperature in
PSS (NaCl 134 mM, KCl 6 mM, CaCl2 2 mM, MgCl2 1 mM, HEPES 10 mM, glucose 10 mM,
pH 7.4 with NaOH). Before taking records, the cells were washed with PSS and further incu-
bated for 20 min to allow de-esterification of the dye.
Pretreatment with 1 μmol/L nimodipine (Sigma-Aldrich) was carried out for 5 minutes
before adding KCl. Fluo-4 loaded cells were imaged using a BioRad MRC 1024 laser scanning
confocal microscope attached to a Nikon Diaphot 300 inverted microscope. Excitation was per-
formed at 488 nm and the emission wavelength was 500 nm. Images were collected at a rate of
1/second. Image processing was done using imageJ 1.41i (National Institutes of Health, USA,
http://rsbweb.nih.gov/ij/). Background fluorescence was subtracted and changes in intracellu-
lar calcium were expressed as relative fluorescence changes, i.e. F/Fo (with Fo indicating the
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fluorescence before stimulation and F the time-dependent fluorescence signal after stimula-
tion). Peak amplitudes of Ca2+ transients were calculated as (Fpeak-Fo)/Fo. Stock solutions of
fluo-4 AM (2.5 mM) and of nimodipine (1 mM) were made using DMSO as solvent. High
external potassium solutions were made by iso-osmotic substitution of NaCl with KCl in the
PSS.
Chemotaxis assay
The chemotaxis assay was performed using modified Boyden chambers (Neuro Probe 48-Well
Micro Chemotaxis Chamber) with fibronectin-coated polyvinylpyrrolidone-free polycarbonate
filter membranes with 8 μm pore size. The lower well of the Boyden chamber was loaded with
chemoattractants (CTGF, b-FGF, PDGF-BB, TGF-β1) diluted in serum-free α-MEM to a final
concentration of 5 ng/mL. Cells from either patients with SSc or healthy donors were cultured
in α-MEM without PL or FCS overnight. Cells were trypsinized and the reaction was stopped
by addition of soybean trypsin inhibitor. 25,000–30,000 cells were added in serum-free α-
MEM to the upper well of the Boyden chamber, and migration was allowed for 25 h. After
scraping off the cells that had not migrated, migrated cells were stained with DiffQuick (Dade
Behring). Membranes were scanned, and cell migration was quantified by densitometry using
ImageJ 1.41i software. Each independent experiment was performed in triplicate.
Cell proliferation assay
5000 cells per well were seeded in 96-well plates in complete α-MEM and allowed to adhere
overnight. The next day, medium was changed to α-MEM without FCS or PL. 24 h later, 10
ng/mL of CTGF, b-FGF, PDGF-BB, or TGF-β1 in α-MEM without FCS or PL were added
together with BrdU (1:500). GF induced proliferation was measured after incubation for
another 24 h as BrdU incorporation with the BrdU cell proliferation kit (Roche) following the
manufacturer’s instructions. All measurements of each independent experiment were per-
formed in five replicates.
Quantification of collagen in cell culture supernatant (SirCol assay)
100 μl cell free supernatants were mixed with 1 ml 0.5 g/l Direct Red (Fluka) in picric acid
(Roth) and incubated at room temperature for 30 min under constant agitation. After centrifu-
gation (5 min, 12,000g), the pellet was washed twice with 1 ml 0.1 M HCl. After the last centri-
fugation step, the pellet was dried and reconstituted in 250 μl 0.5 M NaOH (Roth). Absorption
was measured in an ELISA-plate-reader at 492 nm. The collagen amount was calculated using
a standard curve derived from several dilutions of collagen I solution (1 mg/ml Biochrom) in
experimental medium. Each independent experiment was measured in duplicate.
Total RNA extraction, cDNA synthesis, and quantitative real-time PCR
Cells were scraped into 1 ml Isol-RNA Lysis Reagent (5Prime) on ice and transferred into 1.5
ml microtubes. After adding 0.2 ml chloroform (Merck), the samples were vigorously mixed
for 30 sec, incubated at room temperature for 3 min, and centrifuged at 12,000g for 15 min at
4°C. 400 μl of the aqueous phase were transferred into a new microtube and thoroughly mixed
with 0.5 ml isopropanol (Merck). Incubation at room temperature for 10 min was followed by
another centrifugation step. After washing the pellet twice with 1 ml 70% ethanol, the pelleted
RNA was dried and solved in 20 μl RNase free water.
The isolated RNA was quantified with a NanoDrop 1000 (Thermo Fisher Scientific) and
adjusted to 0.1 μg/μl. Integrity was verified by electrophoretic separation of 200 ng RNA in 1%
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agarose gel. cDNA was synthesized from 500 ng RNA using a reverse transcription system
(Applied Biosystems, Foster City, CA) with 2 μM random hexamers (Applied Biosystems) and
0.2 mM dNTP mix (Promega). Real-time PCR was performed in the 7500 Fast Real-Time PCR
system (Applied Biosystems). The reaction was carried out in 20 μl reaction volumes including
2 μl of cDNA, primers (concentrations as given below; TIB MolBiol, Berlin, Germany) and
10 μl of Power SYBR Green PCRMaster Mix (Applied Biosystems). The PCR program con-
sisted of 2 min at 50°C, 95°C for 10 min followed of 40 cycles 95° for 15 sec and 1 min at 60°C.
Specificity of the reaction was verified by melting curve analysis at the end of each series of
assays.
All primers were designed according to the data given by the National Center for Biotech-
nology Information (NCBI) with assistance of the software Primer3 (http://primer3.
sourceforge.net/releases.php). Quantification was performed via ΔΔCT-method in comparison
to GAPDH as reference gene which was shown not to be regulated by the different treatments
in extensive set up experiments. Primer sequences can be found in the online supplement.
ELISA for TGF-β1
The concentration of TGF-β1 in cell culture supernatant was determined using the human
TGF-β1 CytoSet (Invitrogen) following the manufacturer’s instructions. All samples were pre-
treated with 1 M HCl for 15 min to convert TGF- β1 into its bioactive form. Each sample was
analyzed in triplicate and quantified in Microsoft Office Excel by means of a corresponding
standard curve with log-log curve fit.
Statistics
All data are expressed as mean + SEM. 2-way ANOVA was performed to test for disease-
growth factor-interaction and was followed by post-testing with Bonferroni's Test with correc-
tion for multiple comparisons (GraphPad Prism version 5.02 for Windows, GraphPad Soft-
ware, San Diego California USA). Significance was considered at a value of p<0.05.
Results
Surface marker expression and multilineage differentiation potential of
SSc-MSCs in comparison to H-MSCs
MSCs from healthy controls and patients with SSc were isolated from bone marrow derived
mononuclear cells by adherence to cell culture plastic. We obtained homogenous populations
of H-MSCs and SSc-MSCs presenting the characteristic MSC surface marker profile with posi-
tivity for CD73, CD90 and CD105 whereas markers of hematopoietic lineages were negative
(Fig 1A). We confirmed mesenchymal multilineage differentiation potential by induction of
osteoblastic (Fig 1B), adipocytic (Fig 1C) and chondroblastic differentiation (Fig 1D) as
required by the standard criteria for MSC research [13]. We did not detect any differences
between MSCs from healthy donors and those from patients with SSc under basal conditions.
MSCmorphology and subcellular organization of the contractile
cytoskeleton in response to SSc lesional growth factors
To test the hypothesis that disease specific alterations of the differentiation competence of a
common mesenchymal precursor cell may contribute to development and progression of both,
vasculopathy and fibrosis in SSc, we studied long-term treatment (6 days) of H-MSCs and SSc-
MSCs with the SSc microenvironment-defining GFs CTGF, b-FGF, PDGF-BB, and TGF-β1.
These GFs have been linked to vasculopathy as well as skin and organ fibrosis in SSc [1, 14].
Abnormal Differentiation Capacity of MSC in SSc
PLOSONE | DOI:10.1371/journal.pone.0153101 April 7, 2016 6 / 18
Non-stimulated H-MSCs and SSc-MSCs had a similar microscopic phenotype characterized
by an irregular shape and prominent sm-α-actin (SMA) positive stress fibers (Fig 2A and 2B)
as we previously demonstrated for resting MSCs from healthy donors [11]. Size, shape, subcel-
lular structure, and SMA expression in both, H-MSCs and SSc-MSCs remained similar to rest-
ing MSCs upon exposure to CTGF (Fig 2A and 2B). In response to b-FGF and PDGF-BB,
H-MSCs and SSc-MSCs transformed into slim, elongated cells with considerably reduced cyto-
skeletal stress fibers. Only PDGF-BB treated cells developed multiple pointed extensions (Fig
2A and 2B). In contrast, TGF-β1 induced large cells with huge amounts of stress fibers result-
ing in a myofibroblast-like flattened appearance without processes (Fig 2A and 2B). H-MSCs
and SSc-MSCs responded to the individual GFs with similar over-all microscopic changes.
Deregulated phenotypic plasticity of SSc-MSC derived vascular smooth
muscle cells and fibroblasts
Despite microscopic similarities, MSCs derived from SSc patients substantially differed from
H-MSCs in disease relevant molecular and functional characteristics comprising VSMC differ-
entiation. Compared to H-MSCs, SSc-MSCs displayed deregulation of the contractile VSMC
program indicated by lack of up-regulation of terminal differentiation markers—SM22α and
smooth muscle calponin (sm-Calponin)—in response to CTGF and by decrease in their
expression upon b-FGF (Fig 3A and 3B). Expression of myosin light chain kinase (MLCK) was
either unaffected upon CTGF or down-regulated by b-FGF in both cell types (Fig 3C). SMA
down-regulation in response to b-FGF was similar in both groups (Fig 3D). In response to
Fig 1. Characterization of mesenchymal stromal cells from healthy controls and patients with systemic sclerosis. A, Representative FACS analysis
of an MSC defining surface marker panel confirming homogeneity of isolated cells.B,Osteoblastic differentiation of MSCs after incubation for 21 days with
osteoblast-induction medium. (Alizarin red S staining, original magnification x100, scale bars = 50 μm) C, Adipocytic differentiation of MSCs after incubation
for 21 days with adipocyte-induction medium. (Oil-Red-O staining, original magnification x200, scale bars = 50 μm) D, Chondroblastic differentiation of MSCs
after incubation for 32 days with chondroblast induction medium. Western blot analysis for chondrocyte specific type II collagen.
doi:10.1371/journal.pone.0153101.g001
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PDGF, both cell types down-regulated expression of all proteins characteristic for contractile
VSMC phenotype (Fig 3A–3D) in a similar manner, as it is well established in the biology of
primary VSMCs [15]. Only SMA levels were down-regulated to a lower extent in SSc-MSCs, as
compared to H-MSCs (Fig 3D). In contrast to the other stimuli applied, TGF-β1 enhanced the
expression of the analyzed contractile proteins especially of MLCK and SMA only in SSc-
MSCs but not in H-MSCs (Fig 3A–3D), implicating a presumable induction of myofibroblast
differentiation.
VSMCs with contractile phenotype and myofibroblasts express a similar spectrum of con-
tractile proteins, yet their functional response to extracellular depolarizing stimuli differs con-
siderably. Hence, we measured functional L-type Cav1.2 Ca2+ channels, a hallmark of VSMC
differentiation, using the specific L-type calcium channel blocker nimodipine. Under basal
conditions, MSCs spontaneously differentiate towards contractile VSMC lineage and display
functional L-type calcium channels (Fig 4A and 4B), as we reported previously [11]. CTGF
maintained L-type calcium channels in MSCs of either origin (Fig 4A and 4C). In response to
b-FGF, both cell types increased nimodipine sensitive Ca2+ influx indicating higher functional
capacity of L-type calcium channels. This effect was significantly stronger in H-MSCs com-
pared to SSc-MSCs (Fig 4A and 4D). In contrast, PDGF-BB and TGF-β1 almost abolished
Fig 2. Phenotypic modulation upon long-term stimulation (6 days) with systemic sclerosis microenvironment defining growth factors. A,
Representative phase contrast photomicrographs from a total of 6 independent experiments are shown. (original magnification x200, scale bar = 50 μm) B,
Representative immunofluorescence images from a total of 6 independent experiments are shown. (green = smooth muscle-α-actin, blue = nuclear DNA
stained with 4',6-diamidino-2-phenylindole (DAPI), original magnification x400, scale bar = 50 μm).
doi:10.1371/journal.pone.0153101.g002
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Fig 3. Expression of contractile proteins in response to treatment with systemic sclerosismicroenvironment defining growth factors. A, SM22αB,
smooth-muscle calponin (sm-Calponin) C,myosin-light-chain-kinase (MLCK)D, smooth muscle-α-actin (sm-Actin). Bars represent the mean+SEM of
densitometrically determined band intensities after normalization to α-tubulin. Densitometric quantification and representative western blots of 6 independent
experiments are shown. Cells hat been treated for 6 days. Control was set to 1. *P<0.05, **P<0.01, ***P<0.001.
doi:10.1371/journal.pone.0153101.g003
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Fig 4. Measurement of functional L-type Cav1.2 Ca2+ channels in response to growth factors. Functional L-type Cav1.2 Ca2+ channels measured as
nimodipine sensitive Ca2+-influx upon depolarisation with 60 mmol/L KCl in response to treatment with systemic sclerosis microenvironment defining growth
factors for 6 days.A, Bars represent the mean+SEM of nimodipine sensitive Ca2+-influx from 3 independent experiments. Control was set to 1. *P<0.05,
**P<0.01, ***P<0.001.B-F, Representative recordings of Ca2+ dependent intracellular fluorescence intensities in response to depolarisation with KCl.
Mean±SEM F/F0 of 30–40 cells per growth factor are plotted against time. Black lines represent tracings without the specific L-type calcium channel blocker
nimodipine, grey lines those obtained after preincubation with 1 mmol/L nimodipine.
doi:10.1371/journal.pone.0153101.g004
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L-type calcium channel dependent intracellular increases in Ca2+ (Fig 4A, 4E and 4F) demon-
strating loss of VSMC like differentiation.
Contractile VSMCs contained in the tunica media of arteries respond to an injury induced
release of GFs with a phenotypic switch towards the “synthetic” phenotype characterized by
coordinated repression of the VSMC contractile gene program and concomitant increases in
migration, proliferation, and production of extracellular matrix proteins [16]. In order to fur-
ther discriminate between the differentiated contractile and the dedifferentiated synthetic state
of VSMCs derived fromMSCs, we assessed migration, proliferation and collagen production.
Neither migration nor proliferation were induced by CTGF in H-MSCs or in SSc-MSCs (Fig
5A and 5B). B-FGF elicited a minor non-significant migratory response only in SSc-MSCs (Fig
5A). Secreted collagen was not altered by CTGF or b-FGF in both, H-MSCs and SSc-MSCs
(Fig 5C). Taken together, CTGF promoted differentiation of VSMCs with a contractile pheno-
type, while b-FGF induced differentiation of VSMCs with a synthetic phenotype in H-MSCs.
Both differentiation responses were deregulated in SSc-MSCs (Fig 5D).
PDGF-BB induced migratory and pro-proliferative responses in both, H-MSCs and SSc-
MSCs, yet less accentuated in SSc-MSCs (Fig 5A and 5B). SSc-MSCs migrated towards a TGF-
β1 gradient without increase in proliferation, while H-MSCs remained sedentary but prolifer-
ated effectively (Fig 5A and 5B). The increase in collagen content upon stimulation with
PDGF-BB was moderate and without statistical significance (Fig 5C). Both cell types and espe-
cially SSc-MSCs responded to TGF-β1 with abundant collagen production (Fig 5C). Different
functional phenotypes of H-MSCs and SSc-MSCs implicate that PDGF-BB and TGF-β1
induced two different MSC derived fibroblast populations (Fig 5D).
Disturbed collagen homeostasis in activated myofibroblasts derived
from SSc-MSCs
SSc-MSCs responded to TGF-β1 with an increase in collagen type I α1 mRNA transcripts (Fig
6A), while H-MSCs increased collagen type III α1 levels (Fig 6B). Transcripts of the collagen
degrading enzyme MMP2 were significantly elevated only in H-MSCs (Fig 6C), and MMP9
mRNA levels were significantly down-regulated only in SSc-MSCs (Fig 6D). We propose a
model where TGF-β1 induced collagen synthesis together with insufficient up-regulation of
MMP-2 and enhanced down-regulation of MMP-9 may result in the net effect of SSc related
excessive collagen content in cultures of myofibroblasts derived from SSc-MSCs (Fig 6E).
Hyperresponsive canonical and noncanonical TGF-β signaling in SSc-
MSCs
Similar amounts of TGF-βmRNA (Fig 7A) and protein (Fig 7B) were produced by SSc-MSCs
and H-MSCs implicating no differences between SSc-MSCs and H-MSCs in autocrine TGF-β
loop regulation. Since CTGF may contribute to persistent TGF-β signaling in SSc [14, 17] we
addressed this possibility in MSCs. We obtained no autocrine CTGF stimulation induced by
TGF-β1 in SSc-MSCs or H-MSCs (Fig 7C). Similarly, neither expression of PDGF isoforms nor
PDGF receptors were differentially regulated in H-MSCs and SSc-MSCs upon treatment with
TGF-β1 (S1A–S1E Fig).
Focus on TGF-β related signal transduction pathways served to explain aberrant collagen
homeostasis. A remarkably strong up-regulation of TGF-β receptor I (TGFBR1) protein in
response to TGF-β1 was detected by western-blots only in SSc-MSCs derived myofibroblasts
(Fig 7D). In clear contrast, TGFBR1 protein levels decreased in H-MSCs (Fig 7D). TGF-β1 had
no influence on expression of TGF-β receptor II in H-MSCs and SSc-MSCs (S1F Fig). Further-
more, stronger induction of the canonical pro-fibrotic SMAD3 pathway demonstrated as an
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increase in SMAD3 phosphorylation by TGF-β1 was detected in SSc-MSCs as compared to
H-MSCs (Fig 7E). AKT and ERK1/2, signaling components of noncanonical pathways
involved in migration and proliferation, were also stronger activated in SSc-MSCs compared to
H-MSCs (Fig 7F and 7G).
Fig 5. Cell functions of mesenchymal stromal cells upon treatment with systemic sclerosis microenvironment defining growth factors. A,
Chemotactic response towards a 5 ng/ml gradient of each growth factor. Bars represent the mean+SEM of 3 independent experiments, 3 replicates each.
Control was set to 1. B, Proliferation measured by BrdU incorporation after stimulation with 10 ng/ml of each growth factor for 24 h. Bars represent the mean
+SEM of 3 independent experiments, 5 replicates each. Control was set to 1. C, Total collagen content in cell culture supernatants after 6 days of treatment
with 10 ng/ml of each growth factor. Bars represent the mean+SEM of 6 independent experiments, 2 replicates each. *P<0.05, **P<0.01, ***P<0.001.D,
Illustration of the induction of specific cell types of vascular smooth muscle cell (VSMC) and fibroblast lineages by systemic sclerosis microenvironment
defining growth factors.
doi:10.1371/journal.pone.0153101.g005
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Fig 6. Measurement of collagen homeostasis as marker of fibrosis.Collagen homeostasis after 6 days of treatment with 10 ng/ml transforming growth
factor-β1 in comparison to undifferentiated mesenchymal stromal cells. Quantitative real-time PCR analysis of mRNA transcripts for the collagen isoform
defining chains Col1A1 (A) and Col3A1 (B) and the collagen degrading enzymes matrix metalloproteinase 2 (C) and matrix metalloproteinase 9 (D). Bars
represent the mean+SEM of 6 independent experiments quantified with the ΔΔCt method in duplicates. *P<0.05, **P<0.01. E, Scheme on how differentially
regulated genes involved in collagen homeostasis may contribute to increased collagen secretion in systemic sclerosis.
doi:10.1371/journal.pone.0153101.g006
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Discussion
We report unique intrinsic alterations of MSCs from SSc patients in their response to key-
mediators (CTGF, b-FGF, PDGF-BB, and TGF-β1) of SSc related vasculopathy and fibrosis.
SSc microenvironmental GFs initiated distinct differentiation processes in MSCs ranging from
VSMCs with contractile or synthetic phenotypes to two functionally different fibroblast popu-
lations. MSCs from SSc patients exhibited deregulated contractile VSMC phenoconversion and
increased commitment towards myofibroblast differentiation. In comparison to H-MSCs,
CTGF failed to promote a contractile VSMC phenotype in MSCs from SSc patients whereas
the synthetic VSMC phenotype in response to b-FGF was facilitated. SSc-MSC derived
Fig 7. Analysis of the Transforming growth factor-β1 signaling network. A, Expression of TGF-β1 mRNA andB, secreted TGF-β1 protein for
assessment of the autocrine TGF-β feedback loop. Bars represent the mean+SEM of 6 independent experiments, 3 replicates each.C, Expression of CTGF
mRNA. Quantitative real-time PCR analysis of mRNA transcripts. Bars represent the mean+SEM of 6 independent experiments quantified with the ΔΔCt
method in duplicates. D, Expression of TGF-β receptor 1 protein. E-G, Induction of canonic and non-canonic TGF-β signaling. E, Phosphorylation of SMAD3
at Ser423/425. F, Phosphorylation of AKT at Ser473.G, Phosphorylation of ERK1/2 at Thr202/Tyr204. Analysis of all experiments was performed after 6
days treatment with 10 ng/ml transformin growth factor -β1. Representative western blots of 6 independent experiments are shown. Bars represent the mean
+SEM of densitometrically determined band intensities after normalization to GAPDH (TGFBR1, pSMAD3) or total kinase (pAKT, pERK). Control was set to
1. *P<0.05, **P<0.01, ***P<0.001.
doi:10.1371/journal.pone.0153101.g007
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myofibroblasts functionally resembled activated SSc lesional fibroblasts featuring increased col-
lagen synthesis and enhanced migratory activity towards TGF-β1. Up-regulation and failure of
ligand-dependent down-regulation of TGFBR1 accompanied by enhanced activation of canon-
ical and non-canonical TGF-β signaling in SSc-MSCs may provide a responsible mechanism.
Our data expand the recent findings of dysfunctional differentiation of SSc-MSCs towards the
endothelial lineage [8] and broaden the concept of SSc-related impaired endogenous regenera-
tive capacity of MSCs. This implies SSc as a prototypic disorder where disease initiation and
progression are related to aberrant progenitor cell function.
Targeting cellular mediators of failed angiogenesis and uncontrolled fibrogenesis including
progenitor cell-based therapies evolve as an important goal in the field of SSc. Exogenous cell
therapies are increasingly facing biological challenges in achieving successful long-term regen-
eration [18]. Better understanding of repair barriers associated with disease-microenvironment
related factors which may neutralize exogenously applied autologous progenitor cells receives
increasing priority. We attempted to model the diseased tissue microenvironment by long-
term stimulation of MSCs with prototypic GFs. We are aware that the number of patients
included may represent a limitation of our study. However, all MSC preparations which were
used displayed similar intrinsic biologic properties including constitutional hyperresponsive-
ness to TGF-β1. SSc-MSCs mounted uniform biologic responses in terms of all differentiation
processes studied and consistent data were also reported in signaling experiments, indepen-
dently whether the skin affection of the individual patient was limited or diffuse, whether the
patient had been treated with glucocorticoids or not, or of patient age. Common disease
denominators of all patients were digital ulcers and pulmonary fibrosis.
Despite some promising reports on autologous application of MSCs in SSc, our findings
and those of others [19] raise concern about the safety of such strategies since maldifferentia-
tion of MSCs can thwart their beneficial effects. If autologous MSCs are to be utilized for the
treatment of SSc related complications, they may not only encounter a hostile microenviron-
ment, but yet may also respond inappropriately to regenerative stimuli as our results suggest.
MSCs from SSc patients responded with impaired physiologic contractile VSMC differenti-
ation to CTGF, and showed in parallel a synthetic phenotype in response to b-FGF. Our focus
on deregulated plasticity of smooth muscle progenitors and thereby potentially disturbed arter-
iogenesis may provide an additional explanation related to the severity of vasculopathy in SSc
as it expands the established concept of limited endothelial cell differentiation potential of SSc-
MSCs [8]. Overall deregulation of a physiologic phenotypic switch of progenitor and resident
cell types involved in vasculogenesis ranging from angiogenesis to arteriogenesis is plausible in
SSc. Endothelial-to-mesenchymal phenotypic transition has also recently been implicated in
the pathogenesis of SSc interstitial lung fibrosis [20]. Pericytes as integral cells of capillaries and
microvessels of all organs have been implicated as a source of progenitor cells in vascular and
tissue maintenance. Lately, it has become clear that pericytes are closely related to MSCs, as
cultured pericytes and MSCs are indistinguishable regarding surface marker expression, bio-
logic functions and in vitro differentiation capacity [21]. Moreover, pericytes carry MSC defin-
ing markers (CD44, CD90, CD73, CD105) in their in vivo niche [22]. These findings led to a
model that considers pericytes and MSCs to represent different pools of the same cell—one
attached to the abluminal side of endothelial cells, the other as “free” perivascular or circulating
cells [23]. The local pericyte derived MSC pool can take part in tissue regeneration as has been
suggested for myogenesis [22], fracture healing [24], and other conditions [25, 26]. On the
other hand, pericytes can substantially contribute to organ damage. For example, fate tracing
studies revealed that interstitial myofibroblasts in kidney fibrosis are derived from local peri-
cytes [27]. In SSc, pericytes/MSCs have been linked to the development of fibrosis [28] and
they may also be involved in tissue calcification [29]. Our results may additionally imply a role
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for SSc-pericytes/MSCs in obliteration of vessels by VSMC like derivatives. We are however
aware that the notion of MSC/pericyte derived lesional cells in SSc in addition to those derived
from residential VSMCs, fibroblasts, and circulating fibrocytes of hematopoietic origin cannot
be sufficiently tested in patients in the near future due to exclusive applicability of fate-map-
ping studies to genetically modified mice [30].
Our final key finding was that TGF-β1 induced myofibroblast differentiation in SSc-MSCs
compared to H-MSCs featured a clear functional dimorphism for almost all parameters studied
including contractile cytoskeletal proteins, collagen homeostasis, and migration, which was
similar to lesional fibroblasts. Likewise, fibroblasts isolated from affected tissue of SSc patients
or from healthy controls differ substantially in biologic functions crucial for the development
of the SSc phenotype. As an example, transcriptional regulation of genes involved in collagen
homeostasis such as type I collagen, collagen degrading matrix metalloproteinase-9 (MMP-9),
and the tissue inhibitor of metalloproteinases-1 (TIMP-1) are dysregulated in SSc lesional
fibroblasts [31]. We found comparable disturbances in TGF-β1 induced SSc-MSCs resulting in
accumulation of extracellular collagen.
Mechanisms responsible for tissue fibrosis in SSc are still incompletely understood and have
been predominantly explained as an escape of SSc lesional fibroblasts to control mechanisms
participating in physiologic wound healing [17]. Our study demonstrates that MSCs from SSc
patients with skin and pulmonary fibrosis possess similar intrinsic biologic properties charac-
terized by constitutional hyperresponsiveness to TGF-β1. SSc-MSCs retained high expression
levels of TGFBR1 protein resulting in strongly induced canonical SMAD pathway and nonca-
nonical ERK1/2 and AKT pathways persisting in SSc-MSCs even for 6 days after the initial
stimulus. In contrast, H-MSCs showed ligand dependent TGFBR1 down-regulation and lack
of hyperactivation of canonical and noncanonical signaling. Increased expression levels of
TGF-β receptor II (TGFBR2) in MSCs from SSc patients under basal conditions and enhanced
SMAD3 activation followed by increased collagen mRNA synthesis was recently independently
reported upon short-term TGF-β1 stimulation (up to 24 h) [19]. Given these short-term stimu-
lation data [19] and our long-term experiments, hyperresponsiveness of SSc-MSCs to TGF-β
involves kinetic differences in TGFBR1 and TGFBR2. Short stimulation with low-concentra-
tion TGF-β1 (1 ng/ml for 6 and 24 h) induced TGF-β1 mRNA and protein only in SSc-MSCs
but not H-MSCs [32], further emphasizing different kinetics in the autocrine TGF-β1 loop of
SSc-MSCs and H-MSCs.
Conclusions
In conclusion, our findings substantiate the concept of disease inherent abnormalities in differ-
entiation capacity and biologic functions of MSCs from patients with SSc. Further refinements
in the molecular understanding of disease-related functional diversity in MSC differentiation
together with targeted approaches modulating disease-related local tissue microenvironment
will be necessary to improve regenerative approaches in severe diseases such as SSc.
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PDGF-D mRNA, D, expression of PDGF-Receptor A mRNA, E, expression of PDGF-receptor
B mRNA, F, Expression of TGF-β-Receptor 2 mRNA. Bars represent the mean+SEM of 6 inde-
pendent experiments quantified with the ΔΔCt method in duplicates. P<0.05, P<0.01,
P<0.001.
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